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At Risk for Huntington's Disease
HD is a genetically caused brain disorder that causes uncontrollable bodily movements and robs
people's ability to walk, talk, eat, and think. The final result is a slow, ugly death. Children of parents
with HD have a 50-50 chance of inheriting the disease. There is no cure or treatment.

Blog Archive
► 2021 (12)
► 2020 (16)
► 2019 (19)
▼ 2018 (16)
▼ December (2)
Roche announces U.S.,
Canada sites for
Phase 3 cli...
Building solidarity in
disease communities’
quest ...
► November (2)
► September (2)
► July (1)
► May (1)
► April (2)
► March (3)
► February (3)
► 2017 (14)
► 2016 (13)
► 2015 (24)
► 2014 (24)
► 2013 (30)
► 2012 (26)
► 2011 (33)
► 2010 (26)
► 2009 (21)
► 2008 (7)
► 2007 (7)
► 2006 (4)
► 2005 (17)

About Me
GENE VERITAS

View my complete profile

HD Links
Huntington's Disease Society
of America
International Huntington
Association

SUNDAY, DECEMBE R 09, 2018

Building solidarity in disease communities’ quest for
better care and treatments: a conversation with a
young tennis award-winner
In disease communities, it’s easy for affected individuals and their families
to become insular as they struggle with the many challenges posed by their
particular illness. To attract the attention and funds needed to combat a
disease, sometimes they even portray their condition as more devastating
than others.
In the Huntington’s disease community, we refer to HD as “the devil of all
diseases,” like a combination of Alzheimer’s, Parkinson’s, and psychiatric
and behavioral disorders, including a high suicide rate. There is no
treatment for stopping disease progression.
However, in the quest to treat difficult chronic illnesses, disease
communities need to build solidarity and learn valuable lessons from one
another. Also, although the causes and symptoms of diseases vary widely,
the different communities share the common cause of overcoming the
limits diseases place on people’s lives.
I had a reawakening about solidarity a year ago this week. At the
University of San Diego (USD), where I’m in my 26th year in the
Department of History, a new advisee, 20-year-old sophomore Garrett
Kurtz, sat in my office as he began to recount his own battle to live with
type 1 diabetes.
Suddenly, Garrett untucked the left side of his shirt to reveal a device
about the size of a small smartphone attached to his waist. He explained
that it was a pump that gave him injections of insulin, which helps convert
sugar in the blood so that it can enter the cells and allow them to use
energy. Type 1 diabetics cannot produce this essential hormone.
I felt an immediate bond with Garrett. I shared a bit of my family’s fight
against HD, including my HD-afflicted mother’s death and my condition as
a gene carrier.
Remarkably, I learned, despite his potentially limiting condition, Garrett
has played competitive tennis since he was seven and a half. By 12, he was
ranked in the top 50 male players in the nation, and in the top ten in
Southern California. He now plays for USD’s men’s team, a top 35 National
Collegiate Athletic Association (NCAA) Division I team.
As Garrett explained, few prominent athletes have diabetes. Choosing the
rare but ingenious combination of a history major and chemistry minor, he
aims to work for a biotech or similar firm with the goal of helping
physically active people, including athletes, better manage their diabetes.
For his efforts, in July Garrett was named one of two 2018 Novo Nordisk
Donnelly Award national winners. The award includes a one-time $7,500
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scholarship towards education, tennis development, and/or medical care.
These and smaller awards go to male and female athletes ages 14-21 who
are in good academic standing, manage diabetes, and play tennis
competitively in tournaments or on their school team.
Garrett received the award from all-time tennis great Billie Jean King, a
type 2 diabetic.
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Garrett Kurtz and Billie Jean King (photo from @USDmtennis)
The inspiration of Billie Jean King
“To receive an award from someone like her was absolutely incredible, and
I’m extremely honored,” Garrett said in a November 14 interview with me
at USD, recalling King as a “trailblazer” in women’s sports, gender
equality, and LGBTQ advocacy.
After speaking with King for an hour, Garrett was inspired by her
personality and positive attitude.
“She was very direct,” he said. “She had an aura of self-confidence. She
talked about how having self-confidence and a vision is something so
important to people of all ages, but especially young people, wherever they
may be in society.”
The awards take their name from Diane Donnelly Stone and Tracey
Donnelly Maltby, two sisters who became college tennis stars and have
lived successfully with type 1 diabetes since childhood. Novo Nordisk, a
Denmark-based global healthcare firm with a focus on diabetes, became
the award’s title sponsor in 2002.
“They want to highlight specifically tennis players who are type 1 diabetics
and basically give them a voice or recognition for what they go through
every day, the struggles that they have to deal with,” Garrett commented.
You can watch my interview with Garrett in the video below.
curehd.blogspot.com/2018/12/building-solidarity-in-disease.html
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'Diabetes Does Not Own Me' - An
Interview with Novo Nordisk
Donnelly Awardee Garrett Kurtz
from Gene Veritas

54:56

Diagnosed with type 1 diabetes
Garrett and his parents discovered that he had type 1 diabetes when he was
seven, just around the same time he started playing tennis in his
hometown of Newport Beach, CA.
“I was extremely thirsty and dehydrated,” he recalled. “I also had lost some
weight. One of the unrelated members of my family had type 1 diabetes
and we had a spare blood sugar test kit in my house. My mom took my
blood sugar and I was extremely high and that was a strong indicator of
what was happening. I was taken to the hospital and diagnosed pretty soon
afterwards.”
Other type 1 symptoms include fatigue and weakness, frequent urination,
extreme hunger, irritability and other mood changes, and blurred vision.
“I think diabetes is a very unique disease, because you cannot take a
medication and just be good for the day,” Garrett said. “It’s a 24/7/365
type of disease where everything that I do – whether it be studying,
exercising, eating, the anticipation of waiting for something, being happy –
diabetes affects it.”
With vigilant management of the disease, today his symptoms are under
control.
Understanding type 1 and type 2
In 2015, more than 30 million Americans had diabetes, 1.25 million with
type 1 and the rest with type 2.
Type 1 was previously known as “juvenile diabetes” but actually affects
more adults than children. It occurs in all ages and ethnic groups.
Garrett explained the differences between the two types.
“Type 1 is an autoimmune disease, which basically means your immune
system attacks part of your body, whereas type 2 comes from your lifestyle,
what you eat, and it’s not necessarily hereditary,” he said. “There’s a whole
host of autoimmune diseases.”
His father has ankylosing spondylitis, believed by some researchers to also
be an autoimmune disease. It has the same genetic marker as type 1
diabetes, but the doctors “don’t know if there’s a link between that and my
diabetes,” Garrett said.
curehd.blogspot.com/2018/12/building-solidarity-in-disease.html
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“Type 1 is something that you cannot control,” Garrett continued.
“Basically what happens with a type 1 diabetic is that your immune system
– and this is the great mystery with type 1 diabetes, whether it’s your
environment or something you eat or it’s just how your body works –
attacks all of your beta cells, which are produced by your pancreas.”
Beta cells produce insulin, Garrett explained. Insulin breaks food,
especially carbohydrates, down into glucose, which is the blood sugar that
diabetics measure by pricking their fingers.
“Insulin attaches itself to the sugar and allows it to get transferred to the
individual cells and allows them to use the energy, for you to function and
exercise,” he said.
Type 1 diabetics must “manually administer” their insulin via injection or a
pump such as Garrett’s.
Type 2 diabetes generally results from an unhealthy lifestyle, including
obesity, lack of exercise, and poor diet.
“A type 2 diabetic is different in the sense that they become insulinresistant,” Garrett explained. “You become so used to consuming so much,
that your body keeps producing more and more insulin. It becomes a point
where it’s like taking too much of a drug. It’s like becoming addicted. You
need more and more and more until the point where the insulin just
doesn’t become effective.”
Unhampered on the court
From 2012 to 2015, another unexpected, painful, episodic condition hit
Garrett, this time sidelining him from competitive tennis. After consulting
with nearly a dozen sports orthopedic specialists and undergoing many
MRI scans, he learned that he had a rare physical abnormality: a blood
vessel was sitting on the nerves of his inner right elbow. In late summer
2015, he underwent a successful surgery to relieve the pain, enabling him
to return to the court.
In 2016, after another tennis player recommended Garrett, USD head
tennis coach Ryan Keckley recruited him for the team.
“With the understanding that he was a top ten player, and understanding
his character, his family, and his love for the game, we decided to offer him
an opportunity to play for USD,” Keckley told me. Since his arrival, Garrett
has played in several important matches for USD. Keckley said he expects
Garrett to compete in the upcoming spring 2019 season.
Receiving the Novo Nordisk Donnelly Award was “really a testament of his
character and his work ethic,” added Keckley, a top player while a student
at the University of Notre Dame. “There are very few athletes that have
been able to manage what he manages, and are successful at it. This gives
him an edge in seeking to go into the field of studying diabetes.”
Given Garrett’s small stature for tennis – 5-7, 150 lbs. – “he needs to be the
little engine that could,” Keckley observed. “He has learned how to be
tougher than his opponents, which is ultimately why he was one of the ten
best players in the country in the 14 and unders.”
Because of Garrett’s careful management of his diabetes, the condition has
not hampered his play, Keckley added.
“If you didn’t know Garrett, you wouldn’t know it was something he dealt
with,” he said.

curehd.blogspot.com/2018/12/building-solidarity-in-disease.html

4/8

11/18/21, 1:49 PM

At Risk for Huntington's Disease: Building solidarity in disease communities’ quest for better care and treatments: a conversation…

Garrett Kurtz at practice (photo courtesy USD Men's Tennis Team)
The hope of managing HD
I told Garrett that we in the HD community hope for the breakthrough that
allows patients to manage the disease in a way not unlike how he controls
his diabetes with his pump. HD is also a 24/7/365 disease. HD patients, I
speculated, might tweak their own administration of drug the way he
does.
Still, to affect HD, a drug must cross the highly protective blood-brain
barrier, a monumental task for drug researchers.
HD drug developers have discussed the possibility of using pumps to
deliver a drug. In 2008, in my first visit to the former Isis Pharmaceuticals,
Inc., now Ionis Pharmaceuticals, Inc., the company’s senior vice president,
Frank Bennett, Ph.D., explained how the company used this approach.
(Click here to read my 2008 report.)
Ionis researchers inserted pumps under the skin of mice, then, for each
mouse, ran a tube into the brain to deliver an experimental gene-silencing
drug. At that time, researchers were considering the use of a hockey pucksized pump placed in the abdomen of HD patients, which would pump the
drug through a tube carefully inserted into the brain.
In our discussion, Dr. Bennett pointed out that people with a number of
conditions such as chronic back pain or diabetes already used
commercially approved pumps. Doctors could use infrared signals to
program the pumps and control the flow of medication and could inject a
new supply into the pump through a port just under the skin.
“It’s obviously not ideal, but considering the severity of this disease, it’s
well worth the inconvenience that these pumps produce,” Dr. Bennett
observed in 2008. “Once patients acclimatize to them, they’re really not
that bothersome.”
A pump instead of spinal taps?
curehd.blogspot.com/2018/12/building-solidarity-in-disease.html
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Indeed, Ionis was exploring the possibility of pumping an HD drug into the
cerebrospinal fluid (CSF), which bathes the brain, via pump. It had already
used one of its drugs to reduce the effects of Lou Gehrig’s disease in test
rodents using this method.
So far, such pumps aren’t being used in HD clinical trial. In its historic,
highly successful Phase 1/2a clinical trial, completed in December 2017,
Ionis injected the drug via lumbar puncture (spinal tap) four times into the
CSF of 46 volunteers, without any serious side effects.
The follow-up Phase 3 trial, to be run by Swiss-based Roche starting in
early 2019, will involve 25 monthly lumbar punctures (click here to read
more).
Delivering drugs via spinal fluid is a new procedure. There are no studies
of the effects of long-term use of spinal taps. I expressed my own concerns
about this.
With its current crucial focus on demonstrating efficacy in the Phase 3
trial, Roche is not yet ready to discuss the hypothetical use of a pump or
other drug-delivery methods such as its proprietary “brain shuttle”
technology (click here to read more).
Medtronic, the medical device and healthcare firm that makes Garrett’s
pump, has conducted HD research but not initiated any clinical trials. It
also makes a pump for delivering drugs into the CSF for treating
conditions such as chronic pain.
A revolution in diabetic care
In our November 2018 conversation, Garrett spoke in great detail about
his use of the Medtronic MiniMed 670G electronic insulin pump and its
companion, linked device, a continuous glucose monitoring sensor.

The Medtronic MiniMed 670G electronic insulin pump (largest device in
photo), continuous glucose monitoring sensor (small device on right), and
blood sugar test kit (on the left)
“It’s like a temporary IV that you have to change every three days,” Garrett
explained. “You put it on a region of subcutaneous fat [fat under the skin]
so that it can absorb and go into your system.
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“And the great thing about the insulin pump – and what makes it great for
being a tennis player and being active – is you can give yourself insulin at
any point in time during the day. I just have to press a few buttons, and I
can configure how much insulin I’m giving myself. The great thing about
the pump is that it allows you to give insulin in very small samples.”
That’s important, Garrett said, because the overall volume of insulin
needed by a diabetic “is not very much.”
The system helps “cover carbs” consumed – plus glucose produced by
normal bodily functions – with small, pre-programmed boluses (doses) of
insulin.
“In a normal person, their pancreas is doing all this automatically,” he
continued. “Every few minutes or every few seconds, your pancreas is
giving you insulin. It also gives you a shot of adrenalin, which also bumps
your blood sugar up.”
Garrett used to prick his finger up to a dozen times per day to measure his
glucose. Now, with the continuous monitoring glucose sensor, he does it
only twice. “My finger pads are in bit better shape now,” he observed,
laughing.
The monitor is also attached to a small area of subcutaneous fat, generally
on the stomach or the back of the arm or hips. It measures blood sugar
every five minutes.
“For a diabetic, that’s extremely helpful for you to understand where you
are and what you need to do,” Garrett said, noting that he can thus both
anticipate and make adjustments and know whether he needs to consume
sugar or insulin.
In this hybrid system, the pump and the sensor “talk to each other,”
Garrett added. There are still technical difficulties, but “it’s revolutionary
in terms of diabetic care, because it’s that first step in trying to get the
artificial pancreas.”
He can also download data from the pump and sensor that allows him to
analyze his blood glucose trends and insulin consumption for continual
adjustments.
Feeling ‘on top of your disease’
The devices have not restricted his life in any way, Garrett said. On the
contrary, as a tennis player, he can avoid having to take insulin shots
during a match.
I asked Garrett what advice he would offer to drug companies working on
neurological disease treatments and the potential of long-term drug
delivery.
Garrett replied that he has recently been thinking more about the
significance of his pump.
The system has allowed him to “fine-tune” his insulin intake, he observed.
“Having a pump kind of makes you feel empowered,” he said. “It makes me
feel like I control my disease. I own the disease. The disease doesn’t own
me.”
With drugs delivered via pump, people with HD and other neurological
disorders could also feel “on top of their disease,” he said.
Disease communities learning from one another
curehd.blogspot.com/2018/12/building-solidarity-in-disease.html
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Now a junior, Garrett turned 21 in October. As a history major and
chemistry minor, he wants to research the history of diabetes and how
medical care for the condition has evolved.
After graduation, he would like to work for a company such as Medtronic
to focus on diabetic product design and sales. He is especially passionate
about mentoring young athletes affected by diabetes. He also envisions
starting a division at a healthcare or biotech firm focused on athletes and
other physically active people with diabetes.
He’s also hoping for progress on the development of the artificial pancreas,
the equivalent of a cure for diabetes.
Likewise, the HD community and other neurological disease communities
anxiously await the first effective treatments.
“Time is of the essence in many of these diseases,” Garrett observed. “The
faster you can bring cutting-edge technology to the patient, the better it is.
Just 50 years ago for diabetes, you were taking your blood sugar by
urinating in a cup. Now I wear a device that literally takes it every five
minutes and beams it to a pump.”
These communities all can learn from one another, Garrett stressed.
I have already learned much from Garrett and his approach to life.
(This holiday season please donate to the American Diabetes
Association and the Huntington's Disease Society of America.)
Posted by Gene Veritas at 5:51 PM
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